Depreeuw et al. characterized 24 endometrial cancer PDX models by engrafting fresh tumor tissues from patients and evaluated PI3K and MEK inhibitor treatments based on tumor mutations [64]. This evidence concerns the gene MAP2K7 and neoplasm.